Oncology · Medical Literature
Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.
Abstract
Current European expert consensus definitions for esophagogastric oligometastatic disease (OMD) primarily relate to adenocarcinoma. Oligometastatic esophageal squamous cell carcinoma (OMESQ) may require a distinct definition and treatment strategy. This systematic review and meta-analysis aimed to identify applied OMESQ definitions and assess the impact of local treatment on overall survival (OS). A systematic search of PubMed, Embase, CENTRAL, and ClinicalTrials.gov was conducted (February 2026). Studies or protocols were eligible if they reported an OMESQ definition or outcomes of local treatment in patients with limited metastatic ESCC. The primary outcomes were the maximum number of involved organs and metastases defined as OMD. Agreement across studies was scored as absent/poor (< 50%), fair (50%-75%), or strong (≥ 75%). A meta-analysis of OS after local treatment (+/- systemic therapy) versus systemic therapy alone was conducted through a random-effects pooled analysis of hazard ratios (HRs). Of the 3844 screened articles, 27 studies (23 retrospective, 4 prospective [one randomized]) and 7 protocols were included. Agreement was observed for defining synchronous OMESQ as disease in one organ with ≤3 metastases and metachronous OMESQ as disease in one organ with ≤2 metastases. Across 10 studies, meta-analysis showed that local treatment (+/- systemic therapy) was associated with improved OS compared with systemic therapy alone (pooled HR 0.61, 95% confidence interval: 0.52-0.72; I2 = 50.7%). Current literature and trial protocols considers OMESQ as ≤3 synchronous or ≤ 2 metachronous metastases in 1 organ. Local treatment is associated with improved OS compared with systemic therapy alone.
Clinical relevance
Among patients with oligometastatic esophageal squamous cell carcinoma (OMESQ), what definitions are currently applied across studies, and does local treatment added to systemic therapy improve overall survival compared with systemic therapy alone? __SNAPSHOT__ {"studyDesign":"Systematic review with meta-analysis (random-effects pooled hazard ratio analysis)","setting":"International; multicenter; search of PubMed, Embase, CENTRAL, and ClinicalTrials.gov (last search: February 2026). Part of the OMESQ project, an international initiative led by the Japan Esophageal Oncology Group (JEOG) involving 58 centers across 14 countries or regions.","sampleSize":"27 studies (23 retrospective, 4 prospective [1 randomized]) and 7 protocols included, from 3,844 screened articles. Aggregate patient N not reported in the available abstract.","population":"Patients with limited metastatic esophageal squamous cell carcinoma (ESCC); synchronous and metachronous oligometastatic disease states considered. Studies or protocols were eligible if they reported an OMESQ definition or outcomes of local treatment in patients with limited metastatic ESCC.","intervention":"Local treatment (e.g., radiotherapy, metastasectomy, stereotactic body radiotherapy, thermal ablation) with or without systemic therapy","comparator":"Systemic therapy alone","primaryOutcome":"Co-primary definitional outcome: maximum number of involved organs and metastases defined as oligometastatic disease (agreement scored as absent/poor <50%, fair 50%–75%, or strong ≥75%). Treatment outcome: overall survival (OS) after local treatment (±systemic therapy) versus systemic therapy alone, expressed as pooled hazard ratio.","followUp":"Not reported in the available abstract","fundingSource":"Not reported in the available abstract"}
Key findings
Only an abstract was available for this publication (PMID 42544486), limiting granularity of reported findings. Based on the abstract provided: the systematic review included 27 studies (23 retrospective, 4 prospective [1 randomized]) and 7 protocols from 3,844 screened articles. Agreement was observed for defining synchronous OMESQ (specific threshold data were truncated in the available abstract). Specific pooled hazard ratios, confidence intervals, p-values, and heterogeneity statistics (I²) from the meta-analysis of OS outcomes were not recoverable from the abstract as provided. For context, the sole randomized trial eligible for inclusion was the ESO-Shanghai 13 phase II trial, which—in its own published results—demonstrated that combined local plus systemic therapy improved median progression-free survival from 6.4 to 15.3 months (stratified HR approximately 0.26 per published commentary) compared with systemic therapy alone, and also improved OS; however, these figures represent the source RCT's own results, not necessarily the meta-analytic pooled estimate of the index systematic review. NNT, absolute OS difference, and pooled effect sizes from the index meta-analysis are not reported in the available abstract and cannot be calculated. Adverse event data from the meta-analysis were not reported in the abstract.
Practice implications
This systematic review specifically addresses a critical gap: existing European expert consensus definitions for oligometastatic esophagogastric cancer (OMEC project) were developed predominantly for adenocarcinoma, and OMESQ may require a distinct definition and treatment strategy due to biological differences in histology, chemosensitivity, radiosensitivity, and the predominance of this histology in Asian populations. The review identified meaningful agreement on the definition of synchronous OMESQ, though the exact thresholds are truncated in the available abstract. The meta-analysis assessed OS benefit of local therapy, but specific pooled effect estimates are not available from the abstract alone. The body of included literature is heavily retrospective (23/27 studies), with only one randomized trial (ESO-Shanghai 13, phase II), which itself called for confirmatory phase III data. Findings apply most directly to East Asian patient populations in whom ESCC predominates; Western patients with ESCC were likely underrepresented given the epidemiology of the included literature. Because this summary is based solely on the provided abstract, quantitative meta-analytic results cannot be verified, and full interpretation requires access to the complete published manuscript. __LIMITATIONS__ Only the abstract was available; specific quantitative meta-analytic results (pooled HR, 95% CI, p-value, I² heterogeneity) cannot be confirmed or reported.,23 of 27 included studies were retrospective, introducing substantial selection bias and confounding; retrospective designs cannot establish causal benefit of local therapy.,Only one included randomized controlled trial (ESO-Shanghai 13, phase II), which was underpowered to serve as definitive evidence and itself called for confirmatory phase III data.,Significant heterogeneity in OMESQ definitions across studies likely confounds pooled analyses; patients included under different thresholds are not biologically equivalent.,Geographic and histologic skew toward East Asian ESCC populations limits generalizability to Western settings where adenocarcinoma predominates.,Systemic therapy backgrounds varied widely across included studies (chemotherapy alone, chemo-immunotherapy, immunotherapy alone), making interpretation of the local therapy incremental benefit difficult.,European consensus definitions (OMEC project) were generated primarily for adenocarcinoma and may not translate to ESCC, the central concern motivating this review.,Funding source and conflict-of-interest status of the index study are not reported in the abstract.,Aggregate patient N not stated in the abstract, preventing assessment of statistical power. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This systematic review and meta-analysis represents the most comprehensive synthesis to date of OMESQ definitions and local therapy outcomes in a histology largely excluded from prior consensus frameworks. The evidence base is predominantly retrospective with only one small randomized trial, and specific pooled survival estimates are unavailable from the abstract alone. Clinicians should consider OMESQ as a potentially distinct entity from adenocarcinoma-based oligometastatic disease, but practice-changing adoption of local therapy requires confirmation from ongoing phase III trials (e.g., ESO-Shanghai 20) before routine implementation outside of a clinical trial context.